ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
March 08 2021 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment
of Susan M. Kanaya, the Company’s Executive Vice President and
Chief Financial and Administrative Officer, to the ChemoCentryx
Board of Directors effective March 2, 2021.
“Susan Kanaya’s many fundamental contributions have
been key to ChemoCentryx’s growth and prosperity,” said Thomas J.
Schall, Ph.D., President and Chief Executive Officer of
ChemoCentryx. “Over many formative years of our enterprise, she
ensured our strong financial position, allowing us to achieve our
operational plans and thus increasing shareholder value while
serving patients’ needs. As a true ‘go-to’ executive, Susan has
been instrumental in growing this organization, which is now at the
cusp of achieving its long-stated goal of being a fully integrated
biopharmaceutical enterprise. To all of this, we now have the great
fortune of adding Susan’s many strengths to our Board.”
Ms. Kanaya has served as ChemoCentryx’s Executive
Vice President, Chief Financial and Administrative Officer since
October 2016 and as Secretary since February 2006. Prior to that
she served as the Company’s Senior Vice President, Finance, and
Chief Financial Officer. Before joining ChemoCentryx, Ms. Kanaya
was the Senior Vice President, Finance, and Chief Financial Officer
at Kosan Biosciences Inc., from 1999 to 2005. Prior to this, she
served in financial management positions at SUGEN, Inc., including
Vice President, Finance, and Treasurer. Ms. Kanaya also served as
Controller with high technology companies and as a public
accountant with KPMG. Ms. Kanaya received her B.S. in business
administration from the University of California, Berkeley.
“I’m honored to be joining the ChemoCentryx Board
of Directors and look forward to playing a larger role in driving
our Company’s growth and supporting its strategic and operational
direction,” said Ms. Kanaya. “We’re at a pivotal point in our
evolution as we near our first commercial launch, and I look
forward to these expanded responsibilities as we continue working
toward delivering on our promise to patients, providers and
shareholders.”
About ChemoCentryxChemoCentryx is
a biopharmaceutical company developing new medications for
inflammatory and autoimmune diseases and cancer. ChemoCentryx
targets the chemokine and chemoattractant systems to discover,
develop and commercialize orally-administered therapies.
ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully
completed a pivotal Phase III trial in ANCA-associated vasculitis
and a New Drug Application is under review by the U.S. Food and
Drug Administration. Avacopan is also in late stage clinical
development for the treatment of severe Hidradenitis Suppurativa
and C3 glomerulopathy (C3G).ChemoCentryx also has early stage drug
candidates that target chemoattractant receptors in other
inflammatory and autoimmune diseases and in cancer.
Forward-Looking
StatementsChemoCentryx cautions that statements included
in this press release that are not a description of historical
facts are forward-looking statements. Words such as "may," "could,"
"will," "would," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "intend," "predict," "seek," "contemplate,"
"potential," "continue" or "project" or the negative of these terms
or other comparable terminology are intended to identify
forward-looking statements. These statements include the Company's
statements regarding the Company’s goal of being a fully integrated
biopharmaceutical enterprise, the achievement of anticipated goals
and milestones, whether avacopan will be approved by the FDA or EMA
for the treatment of ANCA-associated vasculitis, and whether the
Company's drug candidates will be shown to be effective in ongoing
or future clinical trials. The inclusion of forward-looking
statements should not be regarded as a representation by
ChemoCentryx that any of its plans will be achieved. Actual results
may differ from those set forth in this release due to the risks
and uncertainties inherent in the ChemoCentryx business and other
risks described in the Company's filings with the Securities and
Exchange Commission ("SEC"). Investors are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and ChemoCentryx undertakes no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof. Further information
regarding these and other risks is included under the heading "Risk
Factors" in ChemoCentryx's periodic reports filed with the SEC,
including ChemoCentryx's Annual Report on Form 10-K filed with the
SEC on March 1, 2021 and its other reports which are available from
the SEC's website (www.sec.gov) and on ChemoCentryx's website
(www.chemocentryx.com) under the heading "Investors." All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.
Contacts:Susan M. KanayaExecutive
Vice President,Chief Financial and Administrative
Officerinvestor@chemocentryx.com
Media:Stephanie
Tomei408.234.1279media@chemocentryx.com
Investors:Burns McClellan, Inc.Lee
Roth212.213.0006lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024